NCT05458674 2026-04-03Tucatinib+Trastuzumab+Eribulin in HER2+ MBCCriterium, Inc.Phase 2 Recruiting30 enrolled
NCT03975647 2026-03-30A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast CancerSeagen Inc.Phase 3 Active not recruiting466 enrolled 17 charts